Ningbo Menovo Pharmaceutical Co (SHSE:603538) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ningbo Menovo Pharmaceutical Co EBITDA Margin % Related Terms
Ningbo Menovo Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co EBITDA Margin % Chart
SHSE:603538 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Menovo Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a EBITDA Margin % of 14.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. This is 36% below median its historical median of 22.00. Over the past decade, Ningbo Menovo Pharmaceutical Co's EBITDA Margin % has ranged from 11.52 to 35.24. According to the industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #498 out of 953 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Ningbo Menovo Pharmaceutical Co's EBITDA Margin % too high?
Ningbo Menovo Pharmaceutical Co's current EBITDA Margin % of 14.16% is 36% below median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 11.52 to a high of 35.24. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Ningbo Menovo Pharmaceutical Co's value of 14.16% is 12.9% above this industry median. Based on the distribution chart, Ningbo Menovo Pharmaceutical Co ranks #498 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #498 out of 953 companies for EBITDA Margin %. This places Ningbo Menovo Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Ningbo Menovo Pharmaceutical Co's value of 14.16% is 12.9% above this benchmark. Historically, Ningbo Menovo Pharmaceutical Co's own EBITDA Margin % has ranged from 11.52 to 35.24 over the past decade. While the company's 10-year median is 22.00 vs. the industry median of 12.54, Ningbo Menovo Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Menovo Pharmaceutical Co's current EBITDA Margin % of 14.16% is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Menovo Pharmaceutical Co's current EBITDA Margin % is 14.16%, which is 36% below median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥22.23, compared to a current price of ¥39.39 — trading 77.2% above its estimated fair value. The current EBITDA Margin % is 14.16%, which is 36% below median its 10-year median of 22.00 and 12.9% above the Drug Manufacturers industry median of 12.54. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current EBITDA Margin % is 14.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥39.39 is trading 77.2% above its estimated GF Value™ of ¥22.23.
GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603538:
EBITDA Margin %: 14.16% (36% below median its 10-year median of 22.00)
GF Value™: ¥22.23 vs. price of ¥39.39 (77.2% above fair value)
Industry Position: 12.9% above the Drug Manufacturers median (#498 of 953)
No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningbo Menovo Pharmaceutical Co Business Description
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
62GF Score
Get the complete analysis for SHSE:603538
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603538 has been successfully added to your 
